ストックスクリーナーアプリを入手
109.23
1.62%
-1.6332
前日終値:
$110.86
開ける：
$110.87
24時間の取引高:
155.27K
Relative Volume:
0.19
時価総額：
$10.51B
収益：
$1.50B
当期純損益:
$47.30M
株価収益率:
-13.95
EPS:
-7.83
ネットキャッシュフロー:
$-527.92M
1週間 パフォーマンス:
-0.04%
1か月 パフォーマンス:
-14.33%
6か月 パフォーマンス:
-15.53%
1年 パフォーマンス:
+29.72%
1日の値動き範囲:
$109.03
$111.78
1週間の範囲:
$102.16
$111.78
52週間の値動き範囲:
$78.67
$173.25
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
名前
Sarepta Therapeutics Inc
セクター
電話
617-274-4000
住所
215 FIRST STREET, CAMBRIDGE, MA
SRPT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| SRPT | 109.23 | 10.51B | 1.50B | 47.30M | -527.92M | -7.83 |
| VRTX | 447.00 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 741.05 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 586.52 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.92 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.72 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-01-31 | 開始されました | BMO Capital Markets | Outperform |
| 2023-12-13 | 再開されました | Citigroup | Buy |
| 2023-12-12 | 開始されました | Deutsche Bank | Buy |
| 2023-11-21 | 開始されました | Wedbush | Outperform |
| 2023-10-31 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-31 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2023-06-23 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2023-04-26 | 開始されました | SMBC Nikko | Outperform |
| 2023-04-04 | 開始されました | Citigroup | Buy |
| 2023-03-01 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-22 | 繰り返されました | BTIG Research | Buy |
| 2022-12-16 | アップグレード | UBS | Neutral → Buy |
| 2022-04-04 | 再開されました | Cantor Fitzgerald | Overweight |
| 2022-01-05 | 繰り返されました | Needham | Buy |
| 2021-12-09 | アップグレード | Oppenheimer | Perform → Outperform |
| 2021-11-05 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-09-15 | アップグレード | Guggenheim | Neutral → Buy |
| 2021-08-05 | アップグレード | JP Morgan | Underweight → Neutral |
| 2021-06-15 | 開始されました | BTIG Research | Buy |
| 2021-04-26 | 再開されました | Credit Suisse | Neutral |
| 2021-01-12 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-01-11 | ダウングレード | UBS | Buy → Neutral |
| 2021-01-08 | ダウングレード | JP Morgan | Overweight → Underweight |
| 2021-01-08 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-01-08 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | 開始されました | Berenberg | Hold |
| 2020-10-28 | 開始されました | UBS | Buy |
| 2020-08-25 | 開始されました | Raymond James | Outperform |
| 2020-08-20 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2020-03-31 | 開始されました | Mizuho | Buy |
| 2019-11-01 | 開始されました | Guggenheim | Buy |
| 2019-08-21 | 繰り返されました | Needham | Buy |
| 2019-07-09 | 繰り返されました | Morgan Stanley | Overweight |
| 2019-07-01 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2019-04-12 | 開始されました | Evercore ISI | Outperform |
| 2019-03-11 | 繰り返されました | Credit Suisse | Outperform |
| 2018-10-12 | 開始されました | Bernstein | Outperform |
| 2018-10-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-09-26 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2018-09-14 | 再開されました | BofA/Merrill | Buy |
| 2018-09-06 | 開始されました | Credit Suisse | Outperform |
| 2018-08-01 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2018-06-21 | 繰り返されました | Robert W. Baird | Outperform |
| 2018-06-20 | 繰り返されました | Needham | Buy |
| 2018-06-19 | 繰り返されました | H.C. Wainwright | Buy |
すべてを表示
Sarepta Therapeutics Inc (SRPT) 最新ニュース
SRPT Beats on Q3 Earnings & Sales, Discontinues PPMO-Based DMD Program - MSN
S&P 500 Futures Climb in Premarket Trading; Target, Fabrinet Lag - Barron's
Sarepta Therapeutics (SRPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates - MSN
Sarepta upgraded at Cantor on pipeline, growth potential - MSN
Sarepta Therapeutics (NASDAQ:SRPT) Cut to Hold at StockNews.com - MarketBeat
Braun Stacey Associates Inc. Grows Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Thrivent Financial for Lutherans Trims Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
FDA endorses speedy approval path for Regenxbio Duchenne gene therapy - Yahoo Finance
Cantor Fitzgerald Upgrades Sarepta Therapeutics (SRPT) - MSN
Aigen Investment Management LP Lowers Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Purchased by Mizuho Markets Americas LLC - MarketBeat
Sarepta Therapeutics, Inc. (SRPT): Among 12 High Growth Large Cap Stocks to Buy Now - Insider Monkey
Simplify Asset Management Inc. Buys 88,474 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
12 High Growth Large Cap Stocks to Buy Now - Insider Monkey
Relative Strength Alert For Sarepta Therapeutics - Nasdaq
Janus Henderson Group PLC's Strategic Acquisition in Sarepta The - GuruFocus.com
Capital International Investors Expands Stake in Sarepta Therape - GuruFocus.com
Sarepta Therapeutics' SWOT analysis: stock poised for growth amid DMD market leadership - Investing.com
Gene Therapy For Rare Disease Market Growth Demand, Segment - openPR
Sarepta Therapeutics (NASDAQ:SRPT) Is Posting Healthy Earnings, But It Is Not All Good News - Simply Wall St
Why Sarepta Therapeutics' (NASDAQ:SRPT) Earnings Are Weaker Than They Seem - Yahoo Finance
Sarepta stops development of exon 51-skipping therapy for DMD - Muscular Dystrophy News
Sarepta recent weakness brings buying opportunity, says JPMorgan - Yahoo Finance
Assetmark Inc. Acquires 27,220 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Principal Financial Group Inc. Decreases Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Sarepta halts development of Duchenne drug as Elevidys soars - The Pharma Letter
Oligonucleotide Therapy Market to Witness Huge Growth by 2031: - openPR
Sarepta Therapeutics: BLA Filing Of SRP-9003 For LGMD Is The Next Step (NASDAQ:SRPT) - Seeking Alpha
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Position Reduced by Fiera Capital Corp - MarketBeat
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q3 2024 Earnings Call Transcript - Insider Monkey
Sarepta price target lowered to $193 from $200 at Baird - Yahoo Finance
Sarepta’s Elevidys Sales Surge, But Next-Gen DMD Drug Platform Discontinued - Citeline
Sparked by FDA expansion, Sarepta's Elevidys takes another leap in sales - FiercePharma
Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Down 7.6% After Analyst Downgrade - MarketBeat
Sarepta Therapeutics (NASDAQ:SRPT) Price Target Raised to $150.00 - MarketBeat
Robert W. Baird Lowers Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $193.00 - MarketBeat
Sarepta sees strong sales on approved Duchenne treatment, stops work on clinical-stage drug - The Business Journals
Sarepta scraps a Duchenne drug as gene therapy sales rise - BioPharma Dive
Sarepta Therapeutics (NASDAQ:SRPT) Price Target Cut to $170.00 by Analysts at Evercore ISI - MarketBeat
Sarepta Halts Development of Next-Gen DMD Drug, Reports Robust Elevidys Sales - BioSpace
Sarepta Therapeutics' (SRPT) Buy Rating Reaffirmed at Needham & Company LLC - MarketBeat
Sarepta Therapeutics To Rally Around 30%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
Van ECK Associates Corp Has $8.85 Million Stock Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Sarepta Therapeutics (NASDAQ:SRPT) Stock Rating Upgraded by Cantor Fitzgerald - MarketBeat
Sarepta Therapeutics (SRPT) Q3 2024 Earnings Call Transcript - Barchart
Sarepta pulls plug on Duchenne exon-skipping drug - pharmaphorum
Sarepta reports strong 3rd-qtr 2024 sales growth - The Pharma Letter
Sarepta Therapeutics Inc (SRPT) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Challenges - GuruFocus.com
Sarepta Therapeutics Inc (SRPT) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Sarepta Therapeutics Announces Third Quarter 2024 Financial Results and Recent Corporate Developments - BioSpace
Sarepta Therapeutics Inc (SRPT) 財務データ
収益
当期純利益
現金流量
EPS
0.42%
0.16%
大文字化:
|
ボリューム (24 時間):